Centessa Pharmaceuticals Plc (CNTA)
NASDAQ:CNTA
Want to see CNTA full AI Analyst Report?
Top Page
Centessa Pharmaceuticals
(NASDAQ:CNTA)
Select Model
Select Model
Rating:58Neutral
Price Target:
$41.00
▲(3.38% Upside)
Action:Reiterated
Date:06/13/26
The score is held back primarily by weak financial performance (no TTM revenue, large losses, and substantial cash burn). Offsetting this are meaningful positive corporate events related to the Eli Lilly acquisition process and moderately constructive technicals, while valuation metrics are unfavorable due to ongoing losses and no dividend signal.
Positive Factors
Low Leverage Balance Sheet
Extremely low leverage gives Centessa durable financial flexibility uncommon for development-stage biotechs. It reduces near-term refinancing risk, supports continued R&D spending or structured M&A outcomes, and preserves optionality while clinical programs advance.
Negative Factors
No Trailing Revenue
Absence of recurring revenue is a fundamental constraint: the company depends entirely on external financing or a transaction to fund operations. This structural lack of operating cash inflows increases vulnerability to funding gaps and limits independent runway for program development.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage Balance Sheet
Extremely low leverage gives Centessa durable financial flexibility uncommon for development-stage biotechs. It reduces near-term refinancing risk, supports continued R&D spending or structured M&A outcomes, and preserves optionality while clinical programs advance.
Read all positive factors
Centessa Pharmaceuticals (CNTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.19B
Dividend YieldN/A
Average Volume (3M)1.32M
Price to Earnings (P/E)―
Beta (1Y)1.17
Revenue Growth-100.00%
EPS Growth1.57%
CountryUS
Employees77
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.78
Shares Outstanding154,728,970
10 Day Avg. Volume1,727,113
30 Day Avg. Volume1,315,918
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)6.44
Price to Sales (P/S)226.28
P/FCF Ratio-17.48
Enterprise Value/Market Cap0.99
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.08K
Enterprise Value/Ebitda-23.47
Forecast
1Y Price Target
$42.40Price Target Upside6.91% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-1.69
Revenue Forecast (FY)N/A
Centessa Pharmaceuticals Business Overview & Revenue Model
Company Description
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, ...
How the Company Makes Money
null...
Centessa Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 15.00M | 0.00 | 6.85M | 0.00 | 0.00 |
| Gross Profit | -467.27K | 15.00M | 0.00 | 6.85M | 0.00 | 0.00 |
| EBITDA | -260.55M | -183.33M | -221.88M | -165.43M | -209.55M | -139.30M |
| Net Income | -250.64M | -197.53M | -235.76M | -151.09M | -216.21M | -381.90M |
Balance Sheet | ||||||
| Total Assets | 641.76M | 687.50M | 576.80M | 360.25M | 444.31M | 629.63M |
| Cash, Cash Equivalents and Short-Term Investments | 276.59M | 294.58M | 482.18M | 256.55M | 393.64M | 595.08M |
| Total Debt | 7.37M | 7.57M | 117.23M | 84.59M | 69.80M | 75.70M |
| Total Liabilities | 154.41M | 160.63M | 175.25M | 124.00M | 108.14M | 138.08M |
| Stockholders Equity | 487.35M | 526.86M | 401.55M | 236.24M | 336.17M | 491.55M |
Cash Flow | ||||||
| Free Cash Flow | -209.17M | -194.19M | -142.09M | -160.51M | -201.68M | -136.33M |
| Operating Cash Flow | -208.79M | -193.82M | -142.06M | -160.34M | -200.55M | -136.14M |
| Investing Cash Flow | -153.44M | -418.53M | 31.27M | -127.00M | -931.00K | 63.25M |
| Financing Cash Flow | 318.91M | 291.53M | 364.75M | 21.12M | 457.00K | 660.07M |
Centessa Pharmaceuticals Technical Analysis
Positive
39.66
Price Trends
39.66
Positive
33.72
Positive
28.96
Positive
Market Momentum
0.22
Positive
69.13
Neutral
79.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CNTA, the sentiment is Positive. The current price of 39.66 is below the 20-day moving average (MA) of 39.79, above the 50-day MA of 39.66, and above the 200-day MA of 28.96, indicating a bullish trend. The MACD of 0.22 indicates Positive momentum. The RSI at 69.13 is Neutral, neither overbought nor oversold. The STOCH value of 79.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CNTA.
Centessa Pharmaceuticals Risk Analysis
Centessa Pharmaceuticals disclosed 116 risk factors in its most recent earnings report. Centessa Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Centessa Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $5.11B | -12.06 | -49.23% | ― | -100.00% | -46.29% | |
58 Neutral | $6.19B | -24.52 | -60.37% | ― | -100.00% | 1.57% | |
58 Neutral | $7.26B | -14.24 | -68.16% | ― | ― | -1.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.70B | -4.53 | 1566.94% | ― | 13.33% | -3.82% | |
50 Neutral | $5.67B | ― | -163.52% | ― | ― | -35.59% |
* Healthcare Sector Average
CNTA
Centessa Pharmaceuticals
40.02
27.59
221.96%
RARE
Ultragenyx Pharmaceutical
27.44
-9.70
-26.12%
XENE
Xenon
52.91
20.86
65.09%
SRRK
Scholar Rock Holding
47.33
13.29
39.04%
IMVT
Immunovant
35.34
19.54
123.67%
Centessa Pharmaceuticals Corporate Events
M&A TransactionsShareholder Meetings
Centessa Shareholders Approve Eli Lilly Acquisition Scheme
Positive
Jun 12, 2026
On June 12, 2026, Centessa Pharmaceuticals’ shareholders overwhelmingly approved the court-sanctioned scheme of arrangement under the U.K. Companies Act through a Scheme Meeting, with 126,653,456 votes in favor and only 23,007 against, pavin...
M&A TransactionsRegulatory Filings and ComplianceShareholder Meetings
Centessa Advances Lilly Acquisition After Key Antitrust Clearance
Positive
May 22, 2026
At 11:59 p.m. on May 21, 2026, the Hart-Scott-Rodino Act waiting period expired for Eli Lilly’s planned acquisition of all issued and to be issued shares of Centessa Pharmaceuticals, clearing a key U.S. antitrust milestone for the deal. The ...
Business Operations and StrategyM&A Transactions
Eli Lilly to Acquire Centessa Pharmaceuticals in Cash Deal
Positive
Apr 1, 2026
On March 31, 2026, Eli Lilly and Company agreed to acquire Centessa Pharmaceuticals via a court-sanctioned scheme of arrangement in the U.K., paying $38 in cash per share plus a non-transferable contingent value right (CVR) worth up to an addition...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.